We attract distinguished and experienced industry professionals.

Our Scientific Advisory Board (SAB) works closely with the M6P Therapeutics’ leadership team to further advance research and development of the company’s innovative pipeline of lysosomal storage disorders (LSDs). By combining the substantial expertise of the SAB with the expertise of the company’s internal R&D team in enzyme replacement therapies and gene therapies, M6P Therapeutics is well positioned to rapidly advance its deep pipeline of LSD programs.

team

Stuart Kornfeld

Washington University. Co-Founder, M6P Tx & Chair, SAB

team

Nancy Dahms

Medical College of Wisconsin

team

Gregory Enns

Stanford School of Medicine

team

Mark Sands

Washington University

team

Anna Tylki-Szymanska

Children's Memorial Health Institute, Warsaw, Poland

team

Raymond Wang

University of California, Irvine School of Medicine